STOCK TITAN

T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences
Rhea-AI Summary
T2 Biosystems, Inc. plans to participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York. The management will present on November 16, 2023, at 8:00am ET. A live and recorded webcast of the presentation will be available on the company's website.
Positive
  • None.
Negative
  • None.

LEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NY.

Management is scheduled to present on Thursday, November 16, 2023, at 8:00am ET. Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the Company’s website at www.t2biosystems.com.

About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, the T2Biothreat™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the expanded T2Bacteria Panel to add Acinetobacter baumannii, the Candida auris test, and the T2Lyme™ Panel, as well as next-generation products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers. For more information, please visit www.t2biosystems.com.

Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406


T2 Biosystems is participating in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York.

The management will present on Thursday, November 16, 2023, at 8:00am ET.

Interested parties can access a live and recorded webcast of the presentation on the 'Investors' section of the T2 Biosystems website.
T2 Biosystems Inc

NASDAQ:TTOO

TTOO Rankings

TTOO Latest News

TTOO Stock Data

Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Small Arms, Ordnance, and Ordnance Accessories Manufacturing
US
Lexington

About TTOO

t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www